Fig. 7: Wnt/β-catenin inhibitor inhibits GBM growth and sensitizes GSCs to IR.

A Vector or LINC00839 overexpressing GSCs were treated with or without celecoxib. Effects on self-renewal were assessed by in vitro extreme limiting dilution assays (ELDA) for sphere formation. * refers to compare between Vector group and LINC00839 group; # refers to compare between LINC00839 group and LINC00839 + celecoxib group. **p < 0.001, ##p < 0.001. B Vector or LINC00839 overexpressing GSCs were treated with or without celecoxib. Representative images of spheres were photographed. Scale bars, 1 mm. C Vector or LINC00839 overexpressing GSCs were treated with or without celecoxib. Cells were treated with IR (0–10 Gy) and seeded in 10 cm dishes. Colonies were counted after 2 weeks, and the surviving fraction was calculated as the ratio of the plating efficiency of the treated cells to that of control cells. **p < 0.001. D Vector or LINC00839 overexpressing MES28 cells were intracranially injected into nude mice (n = 10 for each group). Schematic diagram of the treatment of radiation and celecoxib in tumor-bearing mice. E Representative images of hematoxylin and eosin stained cross-sections of tumor-bearing brains after radiation and celecoxib treatment. F Kaplan–Meier survival curves of immunocompromised mice-bearing intracranial injected GSCs after radiation and celecoxib treatment. **p < 0.001. G, H Representative IHC images and the quantification of Ki-67 (G) and γ-H2AX (H) were shown. Scale bars, 60 μm. **p < 0.001. I Representative TUNEL images and the quantification were shown. Scale bars, 50 μm. **p < 0.001.